NGM Biopharmaceuticals stock (US62921N1006): takeover by Morningside drives new chapter

NGM Biopharmaceuticals has agreed to be acquired by a Morningside affiliate, marking a strategic shift for the biotech focused on liver and oncology programs. What this deal means for shareholders and the pipeline is now in focus.

NGM Biopharmaceuticals is entering a new phase after agreeing to be acquired by an affiliate of long?time investor Morningside on May 1, 2024, in an all?cash transaction that will take the biotech private, according to a company press release published the same day NGM Biopharmaceuticals IR as of 05/01/2024. The deal followed a strategic review and effectively shifted the story for the liver and oncology?focused drug developer away from the public markets.

The merger agreement came after NGM Biopharmaceuticals had already announced in late 2023 that it was exploring strategic alternatives, including partnerships, asset sales or a potential sale of the company, reflecting the challenging funding climate for early?stage biotech firms, as noted in a November 9, 2023 update NGM Biopharmaceuticals IR as of 11/09/2023. The Morningside deal has since framed investor discussion around the value of NGM’s clinical pipeline versus the risks of continuing as a standalone public company.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: NGM Biopharmaceuticals
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: South San Francisco, United States
• Core markets: Liver disease, oncology and metabolic disease drug development
• Key revenue drivers: Collaboration payments, milestones and potential future product royalties
• Home exchange/listing venue: Nasdaq (ticker: NGM), prior to going?private transaction
• Trading currency: USD

NGM Biopharmaceuticals: core business model

NGM Biopharmaceuticals operates as a clinical?stage biopharmaceutical company focusing on developing novel therapeutics for serious diseases, with an emphasis on liver and oncology indications. Its business model centers on advancing a pipeline of antibody and engineered protein therapies that target key biological pathways, while using partnerships to share development risk and generate non?dilutive funding. Historically, the company worked closely with larger pharmaceutical partners such as Merck for discovery and early development activities, retaining certain rights to commercialize or co?develop select assets.

As a research?driven biotech, NGM Biopharmaceuticals does not yet rely on product sales but instead on collaboration revenue, research funding and milestone payments from licensing or partnership agreements. This model is typical in the US biotech sector, where smaller innovators provide early?stage scientific know?how and larger partners offer late?stage development and commercialization muscle. For NGM, this approach allowed the company to pursue multiple programs simultaneously, despite the high cost and risk associated with clinical trials.

However, the end of a long?standing collaboration with Merck in 2023 and more challenging equity capital markets made it harder for NGM Biopharmaceuticals to fund its pipeline solely through public market financing. That shift contributed to management’s decision to launch a formal review of strategic alternatives in November 2023, as disclosed in the company’s announcement on that date. The subsequent agreement for Morningside to acquire NGM and take it private reflects a move toward a different capital structure and ownership model.

Under private ownership, NGM Biopharmaceuticals is expected to refocus resources on priority programs without the quarterly reporting pressures of the public markets. The Morningside transaction provides cash to public shareholders and consolidates control of the pipeline under a single long?term investor. While specific post?deal plans were not detailed in the initial announcement, the company highlighted the opportunity to continue pursuing innovative therapies for patients, while Morningside brings a track record of investing in early?stage life sciences companies.

Main revenue and product drivers for NGM Biopharmaceuticals

Before the going?private transaction, NGM Biopharmaceuticals generated modest revenue primarily from research and collaboration payments, rather than commercial product sales. In its third?quarter 2023 financial update released on November 9, 2023, the company reported revenue of 6.4 million USD for the quarter, driven mainly by its remaining collaboration arrangements, according to the same update NGM Biopharmaceuticals IR as of 11/09/2023. Operating expenses were dominated by research and development, reflecting the company’s focus on clinical trials and pipeline progression.

Key potential future revenue drivers have historically included drug candidates in liver and oncology indications. Among them, NGM621, a monoclonal antibody targeting complement C3, was being evaluated in geographic atrophy, an advanced form of age?related macular degeneration, in a Phase 2 trial whose topline data were discussed by the company in its 2022 and 2023 updates. Another candidate, NGM707, is a dual ILT2/ILT4 antagonist antibody being developed for oncology indications, with early?stage clinical data providing signals of activity that the company aimed to build upon. While none of these candidates had yet reached commercialization, they represented potential long?term value sources if successfully brought to market.

Because NGM Biopharmaceuticals remained in the clinical stage, near?term cash flows depended more on its ability to secure partnerships and licensing deals than on drug sales. For example, the historical Merck collaboration had provided substantial research funding and option payments over several years. As that partnership wound down, the company needed either new partners or significant capital from investors to keep pushing programs through the clinic. The Morningside acquisition effectively replaces the public equity market as the primary funding channel, positioning NGM to progress its most promising candidates without relying on frequent share offerings.

For US investors, understanding these drivers is relevant even after the take?private transaction, because NGM Biopharmaceuticals illustrates how capital cycles and partnership structures can influence the trajectory of small?cap biotech stocks listed on exchanges like Nasdaq. Biotechs with similar profiles often face comparable trade?offs between dilution, strategic deals and potential sales to larger investors or pharmaceutical companies, making NGM’s path a case study in sector dynamics.

Conclusion

The acquisition of NGM Biopharmaceuticals by a Morningside affiliate marks a significant turning point for the company and effectively closes its chapter as a publicly traded biotech on Nasdaq. The move follows a period of strategic uncertainty, after the end of a major collaboration and a challenging funding environment for early?stage drug developers. While the transaction offers liquidity to existing shareholders and a potentially more stable funding base under private ownership, it also means that future value creation from NGM’s pipeline will largely occur outside the public markets. For observers of the US biotech sector, NGM Biopharmaceuticals remains an example of how scientific ambition, partnership structures and capital availability can combine to shape corporate outcomes without constituting a clear template for future investment decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.